Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Psychiatry
Erschienen in: Current Treatment Options in Psychiatry 4/2022

01.12.2022 | Novel Therapeutics in Mood Disorders (R Mansur, Section Editor)

Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence

verfasst von: Mary E. Kittur, BA (Hons), Brett D. M. Jones, MD, MSc, Nasia Dai, BSc (Hons), Mariam Mahboob, BSc (Hons), Muhammad I. Husain, MBBS, MD(Res.), MRCPsych

Erschienen in: Current Treatment Options in Psychiatry | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide an updated summary on the field of immunopsychiatry as it pertains to clinical and therapeutic translation in mood disorders (major depressive disorder [MDD] and bipolar disorder [BD]).

Recent Findings

An updated scoping review of a previous publication by Jones et al. identified five recently published RCTs that continue to explore the anti-depressive efficacy of established immunomodulating agents (minocycline, celecoxib, and aspirin). Consistent with our earlier scoping review, study results remain conflicting, and there is still insufficient support for the clinical utility of any anti-inflammatory agent for the treatment of mood disorders.

Summary

Despite extensive evidence supporting a pathophysiological association between inflammatory activation and depressive symptoms, the repurposing of anti-inflammatory agents as novel antidepressant treatments is still an unrealized goal. As highlighted across scoping reviews, published clinical trials remain insensitive to the inherent heterogeneity of patients with mood disorders. We suggest that more nuanced methodological approaches, such as stratification of participants by inflammatory tone or clinical presentation, are required before real translational advances can be made.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization, 2017.
2.
Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–40.PubMed
3.
Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39(6):653–65.PubMedPubMedCentral
4.
Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171(4):453–62.PubMed
5.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association, 2013.
6.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
7.
Kennedy SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008;10(3):271–7.PubMedPubMedCentral
8.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.PubMed
9.
Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–59.PubMed
10.•
Jones BDM, Daskalakis ZJ, Carvalho AF, Strawbridge R, Young AH, Mulsant BH, et al. Inflammation as a treatment target in mood disorders: review. BJPsych Open. 2020;6(4): e60. A scoping review of published RCTs in the field of immunopsychiatry from inception to 2019, to which the present review serves as an update.PubMedPubMedCentral
11.
Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357(9270):1777–89.PubMed
12.
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.PubMedPubMedCentral
13.
Fleshner M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav Immun. 2013;27(1):1–7.PubMed
14.
Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun. 2003;17(1):13–9.PubMed
15.
D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factorα signaling during peripheral organ inflammation. J Neurosci. 2009;29(7):2089–102.PubMedPubMedCentral
16.
Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci. 1998;18(6):2247–53.PubMedPubMedCentral
17.
Miller AH, Haroon E, Felger JC. Therapeutic implications of brain-immune interactions: treatment in translation. Neuropsychopharmacology. 2017;42(1):334–59.PubMed
18.
Banks WA. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun. 2015;44:1–8.PubMed
19.
Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35(4):298–306.PubMed
20.
Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234–56.PubMedPubMedCentral
21.
Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatrica Scandanavia. 2015;132(3):180–91.
22.
Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175–89.PubMed
23.
Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020;6(1):69.PubMed
24.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40.PubMed
25.
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatrica Scandanavia. 2017;135(5):373–87.
26.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.PubMed
27.
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.PubMedPubMedCentral
28.
Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 1999;65(17):1773–86.PubMed
29.
Kubera M, Simbirtsev A, Mathison R, Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 2000;96(3):255–66.PubMed
30.
Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531–43.PubMed
31.
Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452–9.PubMedPubMedCentral
32.••
Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224–44. A comprehensive review of evidence linking inflammatory elevation to MDD, including purported biological mechanisms.PubMedPubMedCentral
33.
Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18(4):225–42.PubMed
34.
Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7(12):1064–74.PubMedPubMedCentral
35.•
Giridharan VV, Sayana P, Pinjari OF, Ahmad N, da Rosa MI, Quevedo J, et al. Postmortem evidence of brain inflammatory markers in bipolar disorder: a systematic review. Mol Psychiatry. 2020;25(1):94–113. A systematic review of post-mortem data evaluating markers of brain inflammation in BD.PubMed
36.
Csölle C, Baranyi M, Zsilla G, Kittel A, Gölöncsér F, Illes P, et al. Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors. PLoS ONE. 2013;8(6):e66547.PubMedPubMedCentral
37.
Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994;51(11):865–74.PubMed
38.
Parrott JM, Redus L, Santana-Coelho D, Morales J, Gao X, O’Connor JC. Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. Transl Psychiatry. 2016;6(10):e918.PubMedPubMedCentral
39.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54(1):70–5.PubMed
40.
Felger JC. The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. Curr Top Behav Neurosci. 2017;31:199–219.PubMed
41.
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24(1):27–53.PubMed
42.
Attwells S, Setiawan E, Rusjan PM, Xu C, Kish SJ, Vasdev N, et al. A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. Transl Psychiatry. 2021;11(1):334.PubMedPubMedCentral
43.••
Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021;46(5):939–48. A recent RCT demonstrating the significance of baseline inflammatory tone when evaluating the anti-depressive effects of immunomodulating agents.PubMedPubMedCentral
44.
Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry. 2020;7(6):515–27.PubMed
45.
Kloiber S, Jones BDM, Hodsoll J, Chaudhry IB, Khoso AB, Husain MO, et al. Metabolic function in patients with bipolar depression receiving anti-inflammatory agents: Findings from the MINDCARE study, a multicentre, randomised controlled trial. J Affect Disord. 2022;299:135–41.PubMed
46.
Halaris A, Cantos A, Johnson K, Hakimi M, Sinacore J. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord. 2020;261:145–52.PubMed
47.
Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2020;129:189–97.PubMed
48.
Morgan G. The established and emerging uses of aspirin. Basic Clin Pharmacol Toxicol. 2006;99(4):283–6.PubMed
49.
Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol. 2007;60(12):1242–9.PubMed
50.
Berk M, Mohebbi M, Dean OM, Cotton SM, Chanen AM, Dodd S, et al. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. BMC Med. 2020;18(1):16.PubMedPubMedCentral
51.•
Yang C, Wardenaar KJ, Bosker FJ, Li J, Schoevers RA. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review. J Affect Disord. 2019;257:640–9. A systematic review of identified peripheral inflammatory markers and their respective utility in predicting treatment response in depression.PubMed
52.
Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones D, Drevets WC, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214(1):11–9.PubMedPubMedCentral
53.
Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: a Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Front Psychiatry. 2019;10:458.PubMedPubMedCentral
54.
Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278–86.PubMed
55.
Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018;95:43–9.PubMedPubMedCentral
56.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370–9.PubMed
57.
Strawbridge R, Arnone D, Danese A, Papadopoulos A, HeraneVives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532–43.PubMed
58.••
Liu JJ, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, et al. Peripheral cytokine levels and response to antidepressant treatment in depression a systematic review and meta-analysis. Mol Psychiatry. 2020;25(2):339–50. A recent review evaluating the role of inflammatory cytokines in anti-depressant response.PubMed
59.••
Lynall ME, Turner L, Bhatti J, Cavanagh J, de Boer P, Mondelli V, et al. Peripheral blood cell-stratified subgroups of inflamed depression. Biol Psychiatry. 2020;88(2):185–96. A paper suggesting distinct immunophenotypes in depression, with implications for symptom severity.PubMed
60.
Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 2011;188(2):224–30.PubMed
61.
Xue S, Hodsoll J, Khoso AB, Husain MO, Chaudhry IB, Young AH, et al. Suicidality in patients with bipolar depression: findings from a lower middle-income country. J Affect Disord. 2021;289:1–6.PubMed
62.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat. 2013;70(1):31–41.
63.
Porcu M, Urbano MR, Verri WA Jr, Barbosa DS, Baracat M, Vargas HO, et al. Effects of adjunctive N-acetylcysteine on depressive symptoms: modulation by baseline high-sensitivity C-reactive protein. Psychiatry Res. 2018;263:268–74.PubMed
64.
Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018;8(1):27.PubMedPubMedCentral
65.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.PubMedPubMedCentral
66.••
Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression. Biol Psychiatry. 2020;88(5):369–80. A review article linking immune dysregulation to atypical symptoms of depression, suggesting a subgroup of patients for whom novel biological targets are particularly indicated.PubMed
67.
Simmons WK, Burrows K, Avery JA, Kerr KL, Taylor A, Bodurka J, et al. Appetite changes reveal depression subgroups with distinct endocrine, metabolic, and immune states. Mol Psychiatry. 2020;25(7):1457–68.PubMed
68.••
Franklyn SI, Stewart J, Beaurepaire C, Thaw E, McQuaid RJ. Developing symptom clusters: linking inflammatory biomarkers to depressive symptom profiles. Transl Psychiatry. 2022;12(1):133. A recent cluster analysis suggesting inflammatory elevation is uniquely implicated in neurovegetative symptoms as compared to other symptoms of depression, suggesting a subgroup of patients for which immunomodulating agents may be clinically relevant.PubMedPubMedCentral
69.
Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1137–48.PubMed
70.
Beydoun MA, Obhi HK, Weiss J, Canas JA, Beydoun HA, Evans MK, Zonderman AB. Systemic inflammation is associated with depressive symptoms differentially by sex and race: a longitudinal study of urban adults. Mol Psychiatry. 2020 Jun;25(6)
71.
Chen Y, Jin M, Shao Y, Xu G. Prognostic value of the systemic inflammation response index in patients with adenocarcinoma of the oesophagogastric junction: a propensity score-matched analysis. Dis Markers. 2019 Nov 4
72.
Ellul P, Mariotti-Ferrandiz E, Leboyer M, Klatzmann D. Regulatory T cells as supporters of psychoimmune resilience: toward immunotherapy of major depressive disorder. Front Neurol. 2018;20(9):167.
73.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019
74.
Jones BDM, Razza LB, Weissman CR, Karbi J, Vine T, Mulsant LS, Brunoni AR, Husain MI, Mulsant BH, Blumberger DM, Daskalakis ZJ. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021 Sep 1;4(9)
75.
Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.PubMed
76.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26:607–11.PubMed
77.
Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo controlled study. J Affect Disord. 2012;141:308–14.PubMed
78.
Majd M, Hashemian F, Hosseinib SM, Shariatpanahi MV, Sharifid A. A randomized, doubleblind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study. Iran J Pharm Res. 2015;14:891–9.PubMedPubMedCentral
79.
McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiat. 2019;76:783–90.
80.
Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, Rasoulinejad M, Zeinoddini A, Yalda A, et al. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol. 2016;31:20–6.PubMed
81.
Husain MI, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol. 2017;31:1166–75.PubMed
82.
Dean OM, Kanchanatawan B, Ashton M, Mohebbi M, Ng CH, Maes M, et al. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. Aust N Z J Psychiatry. 2017;51:829–40.PubMed
83.
Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder. J Clin Psychiatry. 2014;75:628–36.PubMed
84.
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-Acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468–75.PubMed
85.
Bauer IE, Green C, Colpo GD, Teixeira AL, Selvaraj S, Durkin K, et al. A double blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry. 2019;80:1.
86.
Ellegaard PK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 2019;245:1043–51.PubMed
87.
Berk M, Turner A, Malhi GS, Ng C, Cotton SM, Dodd S, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019;17:18.PubMedPubMedCentral
Metadaten
Titel
Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence
verfasst von
Mary E. Kittur, BA (Hons)
Brett D. M. Jones, MD, MSc
Nasia Dai, BSc (Hons)
Mariam Mahboob, BSc (Hons)
Muhammad I. Husain, MBBS, MD(Res.), MRCPsych
Publikationsdatum
01.12.2022
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Psychiatry / Ausgabe 4/2022
Elektronische ISSN: 2196-3061
DOI
https://doi.org/10.1007/s40501-022-00267-1

Weitere Artikel der Ausgabe 4/2022

Current Treatment Options in Psychiatry 4/2022 Zur Ausgabe

PTSD (S Frankfurt, Section Editor)

Neuromodulation as an Augmenting Strategy for Behavioral Therapies for Anxiety and PTSD: a Narrative Review

Moral Injury (JI Harris, Section Editor)

Moral Injury in the Context of Substance Use Disorders: a Narrative Review

Social Determinants of Health (R Holliday, Section Editor)

The Importance of Context: Using Social Determinants of Health to Improve Research and Treatment of Posttraumatic Stress Disorder

Moral Injury (JI Harris, Section Editor)

Building Spiritual Strength: a Spiritually Integrated Approach to Treating Moral Injury

Social Determinants of Health (R Holliday, Section Editor)

Characterizing Social Determinants of Health in Research Regarding the Clubhouse Model for Individuals with Mental Health Conditions

Invited Commentary

MAOI or ECT? Patient Preference and Joint Decision-Making in Treatment-Resistant Depression

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise